IN8bio, Inc. (INAB)
NASDAQ: INAB · Real-Time Price · USD
1.970
-0.030 (-1.50%)
At close: Jan 30, 2026, 4:00 PM EST
2.000
+0.030 (1.52%)
After-hours: Jan 30, 2026, 7:59 PM EST
IN8bio Employees
IN8bio had 17 employees as of September 30, 2025. The number of employees decreased by 1 or -5.56% compared to the same quarter last year.
Employees
17
Change
-1
Growth
-5.56%
Revenue / Employee
n/a
Profits / Employee
-$1,215,176
Market Cap
19.24M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 17 | -1 | -5.56% |
| Jun 30, 2025 | 18 | -21 | -53.85% |
| Mar 31, 2025 | 18 | -16 | -47.06% |
| Dec 31, 2024 | 18 | -13 | -41.94% |
| Sep 30, 2024 | 18 | -13 | -41.94% |
| Jun 30, 2024 | 39 | 10 | 34.48% |
| Mar 31, 2024 | 34 | 6 | 21.43% |
| Dec 31, 2023 | 31 | 5 | 19.23% |
| Sep 30, 2023 | 31 | 5 | 19.23% |
| Jun 30, 2023 | 29 | 8 | 38.10% |
| Mar 31, 2023 | 28 | 7 | 33.33% |
| Dec 31, 2022 | 26 | 7 | 36.84% |
| Sep 30, 2022 | 26 | 13 | 100.00% |
| Jun 30, 2022 | 21 | 7 | 50.00% |
| Mar 31, 2022 | 21 | 7 | 50.00% |
| Dec 31, 2021 | 19 | 5 | 35.71% |
| Sep 30, 2021 | 13 | 6 | 85.71% |
| Mar 31, 2021 | 14 | 7 | 100.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| CASI Pharmaceuticals | 233 |
| BioAtla | 61 |
| Lunai Bioworks | 29 |
| Quantum BioPharma | 17 |
| VYNE Therapeutics | 13 |
| Lexaria Bioscience | 7 |
| Allarity Therapeutics | 7 |
| Pasithea Therapeutics | 4 |
INAB News
- 18 days ago - IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma - GlobeNewsWire
- 6 weeks ago - IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager - GlobeNewsWire
- 3 months ago - IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 3 months ago - IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site - GlobeNewsWire
- 3 months ago - IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications - GlobeNewsWire
- 6 months ago - IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 8 months ago - IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial - GlobeNewsWire
- 8 months ago - IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival - GlobeNewsWire